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Abstract
Vector-borne viruses are an important class of emerging and re-emerging pathogens; thus, an improved understanding of the
cellular factors that modulate infection in their respective vertebrate and insect hosts may aid control efforts. In particular, cell-
intrinsic antiviral pathways restrict vector-borne viruses including the type I interferon response in vertebrates and the RNA
interference (RNAi) pathway in insects. However, it is likely that additional cell-intrinsic mechanisms exist to limit these viruses.
Since insects rely on innate immune mechanisms to inhibit virus infections, we used Drosophila as a model insect to identify
cellular factors that restrict West Nile virus (WNV), a flavivirus with a broad and expanding geographical host range. Our
genome-wide RNAi screen identified 50 genes that inhibited WNV infection. Further screening revealed that 17 of these genes
were antiviral against additional flaviviruses, and seven of these were antiviral against other vector-borne viruses, expanding
our knowledge of invertebrate cell-intrinsic immunity. Investigation of two newly identified factors that restrict diverse viruses,
dXPO1 and dRUVBL1, in the Tip60 complex, demonstrated they contributed to antiviral defense at the organismal level in
adult flies, in mosquito cells, and in mammalian cells. These data suggest the existence of broadly acting and functionally
conserved antiviral genes and pathways that restrict virus infections in evolutionarily divergent hosts.
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Introduction
Historically, West Nile virus (WNV) epidemics were observed in
Africa, the Middle East, Europe, India, Australia, and parts of Asia,
In 1999, WNV entered into the North America as part of an
outbreak of neuroinvasive disease in New York City [1], and since
then has become endemic in the United States with large numbers of
cases occurring annually in different regions of the country. Indeed,
the occurrence, size, and severity of outbreaks in humans overall
have increased worldwide since the mid 1990s [2], with a large
outbreak in Texas in 2012 leading to many fatalities [3,4]. Different
strains of WNV, with variable worldwide distributions, exhibit
significant differences in pathogenesis. In humans infected with
North American WNV strains, approximately 80% of infections are
asymptomatic, with 20% developingWNV fever and other relatively
mild symptoms, and 1% progressing to encephalitis, meningitis, or
flaccid paralysis [2]. In contrast, WNV-Kunjin, endemic in
Australia, has not been associated with any human fatalities or
severe disease [5]. The natural transmission cycle of WNV is
between mosquitoes and birds, with humans, horses, and other
vertebrates being incidental dead-end hosts [2]. WNV is a member
of the Flavivirus genus, which includes many globally important
vector-borne pathogens, such as Dengue (DENV), yellow fever
(YFV), tick-borne encephalitis (TBEV), and Japanese encephalitis
viruses (JEV) [6]. DENV is endemic in more than 110 countries with
3.6 billion people at risk, and 390 million people infected yearly
[7,8]. At present, there are no specific antiviral therapies against any
flavivirus, and only three insect-borne flaviviruses have approved
vaccines for humans (YFV, TBEV, and JEV) [9].
Flaviviruses are small (,50 nm diameter) enveloped viruses that
contain a single-stranded, positive-sense RNA genome of ,11-kb
with a 59 cap, but unlike mRNA, lack a 39 polyadenylated tail
[10]. WNV enters both vertebrate and invertebrate cells through
clathrin-mediated endocytosis [11], and then traffics to an acidic
compartment that facilitates viral fusion with endosomal mem-
branes and release of the nucleocapsid into the cytoplasm [12].
The viral genome encodes one open reading frame and is
translated as a single polyprotein at the rough endoplasmic
reticulum (ER), which is subsequently processed by both viral and
cellular proteases into 3 structural and 7 non-structural viral
proteins [13]. Viral RNA replication occurs within cytoplasmic
complexes associated with perinuclear membranes requiring lipid
rearrangements [14,15,16,17], and progeny viruses bud into the
ER and traffic through the Golgi network where virions are
processed into mature particles prior to exocytosis [18].
While there has been extensive study into the cellular pathways
that are hijacked to facilitate WNV infection in mammalian cells,
less is known about the cell-intrinsic pathways that restrict WNV
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in insects and whether these pathways have conserved roles in
vertebrates. Furthermore, Flaviviruses belong to a larger group of
vector-borne RNA viruses (including Togaviruses and Bunyavi-
ruses), raising the possibility that these viruses as a group may be
restricted using shared host defense pathways. Indeed, RNA
interference (RNAi) is recognized as a major antiviral mechanism
in insects and is active against all human arthropod-borne viruses
tested including the flaviviruses WNV and DENV [19,20]. The
Jak-STAT and Toll pathways also are active in diverse insect hosts
and restrict flavivirus infection in mosquitoes [19,20]. Indeed,
many antiviral pathways active in vector insects were first shown to
restrict viral infection in the fruit fly (Drosophila melanogaster) model.
This is in part due to the depth of Drosophila genome annotation,
powerful genetic tools, potent gene silencing by RNAi, limited
genetic redundancy, a high percentage of identifiable functional
orthologs in both mosquitoes and vertebrates, lack of an acquired
immune system, and that Drosophila can be experimentally infected
by a large number of human arthropod-transmitted viruses.
Furthermore, RNAi screening is robust in Drosophila cells and has
been used effectively to analyze host-pathogen interactions and
identify genes involved in antiviral defense including components
of the RNAi silencing machinery [21,22,23,24]. Additionally,
findings in Drosophila have been extended to mosquitoes and
mammals further validating this approach [23,24,25,26,27,
28,29,30,31].
In this study, we used Drosophila to identify cell-intrinsic
antiviral genes that restrict WNV and hypothesized that a number
of these would restrict other insect-borne viruses, and some might
have conserved roles in vector insects such as mosquitoes. Since
many antiviral pathways (e.g., autophagy, Jak/Stat and Toll
pathways) are active both in mammals and insects, we speculated
that some of these newly identified factors also would confer
antiviral activity in mammalian cells. To identify such genes using
an unbiased approach we performed a genome-wide high-content
RNAi screen in Drosophila cells to identify cellular factors that
limited WNV infection. To date, RNAi screens have mainly
focused on cellular factors usurped by pathogens to promote
infection. While 22 restriction factors have been identified as anti-
flaviviral in genome-wide RNAi screens [24,32], only 2 of these
are conserved between humans and insects. We optimized the
assay for the discovery of restriction factors and identified 50 genes
that when silenced resulted in enhanced WNV infection in
Drosophila cells. All 50 are conserved in mosquitoes and 86% have
clearly defined human orthologs. Furthermore, 17 of these genes
had antiviral activity against multiple flaviviruses, and 7 genes
were antiviral against a diverse panel of additional vector-borne
RNA viruses. We focused on two broadly acting conserved genes,
dRUVBL1 (pontin) and dXPO1 (embargoed), and found both
restricted viral infection in adult flies, were antiviral in mosquito
Aedes aegypti cell culture as well as in human cells. Furthermore,
since WNV is neurotropic we tested whether RUVBL1 contrib-
utes to control of WNV in neurons and found it to be antiviral in
these cells. Mechanistically, our studies establish that dRUVBL1
along with other members of the Tip60 histone acetylase complex
are antiviral suggesting a role for this complex in virus restriction.
Furthermore, we found that dXPO1 controls the nuclear export of
specific host mRNAs, including the mRNA encoding Aldolase,
which we identified as antiviral. Collectively, we identified
additional novel, broadly acting cell-intrinsic antiviral genes in
Drosophila at least some of which function in mosquito and
vertebrate cells.
Results
RNAi screening of WNV infection of Drosophila cells
To identify cellular factors that restrict WNV infection, we first
characterized the infection of a pathogenic North American WNV
isolate (New York 2000) (referred to as WNV) [33], in Drosophila
DL1 cells. WNV successfully infected and produced infectious
virions from DL1 cells, although infection levels were substantially
lower than that observed in human cells (Figure S1A and B in
Text S1). Kinetic experiments revealed that peak immunofluo-
rescence signal of virally produced NS1 protein was 48 hours post
infection (hpi), a time point prior to substantial virus spread
(Figure S1B and C in Text S1). We next tested whether WNV
infection of Drosophila cells was dependent on similar entry and
replication pathways as in mammalian and mosquito cells.
Chlorpromazine, an inhibitor of clathrin-mediated endocytosis,
blocks entry of WNV in both mammalian and mosquito cells
[34,35], and also effectively inhibited WNV infection of Drosophila
DL1 cells (Figure S1D in Text S1). Ribavirin, a nucleoside
analog and a inhibitor of Flavivirus replication in many
mammalian cell types [36], also inhibited WNV infection of
Drosophila cells (Figure S1E in Text S1).
Next, we optimized RNAi in a 384-well format using dsRNAs
against b-galactosidase (bgal) as a negative control, and dsRNA
against the WNV genome as a positive control (Figure 1A and
B). We also included dsRNA targeting Ars2, a gene that we
previously established as antiviral in Drosophila against many
unrelated RNA viruses [21]. By selecting the infection level at
,7%, this maximized the fold-change in infection upon loss of
Ars2, allowing us to focus the assay on genes which restrict
infection. This approach contrasts with previous screens that used
a higher infection level and focused on genes that promote
infection [24,32]. Briefly, DL1 cells were seeded onto 384 well
plates pre-arrayed with dsRNAs, incubated for 3 days for effective
knockdown of target genes, and infected with WNV (Multiplicity
of infection (MOI) of 10) for 48 hours. Cells were fixed,
permeabilized and stained for the viral protein NS1 [37] and
counterstained for nuclei. Automated microscopy and image
analysis calculated the cell number per well (nuclei) and number of
infected cells (WNV NS1) to measure the percent infection. As
Author Summary
West Nile virus (WNV) is an insect-borne virus that has re-
emerged globally and for which there are no specific
therapeutics or vaccines. We set out to identify cellular
factors that impact infection using Drosophila as a model
insect. Using a genome-wide RNAi screen we identified a
large number of genes that altered WNV infection. We
focused on genes that restricted infection and validated 50
genes that were conserved from insects to humans that
inhibited infection. Since WNV is a flavivirus, we tested
whether additional flaviviruses were restricted by these
genes and found that 17 also had antiviral activity against
Dengue virus. There are additional families of insect-
transmitted viruses that infect humans. Accordingly, we
tested whether these genes also were antiviral against the
bunyavirus Rift Valley Fever virus, the alphavirus Sindbis
virus and the rhabdovirus Vesicular Stomatitis virus. From
this analysis, we identified seven genes that are antiviral
against all of these divergent arthropod-borne pathogens
expanding our knowledge of cell-intrinsic immunity in
insects. Lastly, we found that XPO1 and the Tip60 complex
had antiviral activity in mammalian cells. These data
demonstrate the existence of previously unknown antiviral
genes that restrict infection of multiple viruses across
divergent hosts.
Broadly-Acting Anti-Arboviral Host Factors
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expected, we observed a decrease in infection after treatment with
dsRNA against WNV. Importantly, we also observed a robust
increase in WNV infection upon loss of Ars2 (Figure 1A and B);
thus these optimized conditions were used for RNAi screening.
A genome-wide RNAi screen was performed in duplicate and
statistical analysis identified 537 genes (3.6% of the Drosophila
genome) that when silenced had a significant effect on the
percentage of WNV infected cells, with a robust Z score of $2 or
#22 in both replicates (p,0.001; ,40% change; Figure 1C).
None of the non-targeting controls spotted on each plate were
identified whereas 100% of the positive control dsRNAs spotted
on each plate against WNV genome and Ars2 were identified.
Silencing of 376 of these 537 genes resulted in decreased viral
infection, indicating WNV was dependent on these genes for
replication (viral sensitivity factors (VSF)). Silencing of 161 genes
resulted in increased WNV infection suggesting they normally
restrict replication (viral resistance factors (VRF)). As WNV infects
mosquitoes, birds, and vertebrates we were interested in those
genes having orthologs in hosts that normally encounter the virus,
rather than genes annotated as Drosophila specific, as flies are not
natural hosts. Analysis of this candidate gene list revealed that
,59% of the genes have orthologs in both humans and
mosquitoes (p,0.0001), with Drosophila-specific genes being greatly
under-represented (,23% of the total; p,0.0001) (Figure 1D).
Of the 537 genes identified in the primary screen, 147 were
cytotoxic (robust Z score,22 in duplicate; ,15% decrease in cell
number) and were excluded from further analysis. Only one gene
had a robust Z score.2 in duplicate but did not validate
subsequently. Additionally, 131 genes were not clearly conserved
in mosquitoes or humans (as determined by Homologene) and also
were excluded from further analysis. Of the 280 remaining genes,
we set out to validate all of the genes except for a handful that were
members of complexes in which we identified .2 components. In
those cases, we chose to validate representative genes from these
complexes (Table S1). To do this, we generated independent
dsRNA reagents that targeted 217 genes and screened this
secondary gene set under two conditions: we infected cells at a
low level of infection (4%) to maximize identification of genes that
restricted infection, and at a higher level of infection (18%) to
maximize validation of genes that promote infection. Of the 217
genes, 121 validated (56%): 82 genes (68%) facilitated WNV
infection (VSFs) and 39 genes (32%) restricted infection (VRFs).
We also validated a total of 23 genes from larger complexes
(Table S1, Table S2, and Figure S1F in Text S1). If we
Figure 1. Genome-wide RNAi screen in Drosophila for host factors involved in WNV infection. A. Representative images of DL1 cells
treated with the indicated dsRNAs and infected with WNV (nuclei, blue; WNV NS1, green). B. Quantification of fold change in infection for dsRNA
treated cells as in A. Mean6 SD for 3 independent experiments; ** p,0.01. C. Schematic of screening pipeline including the scatter plot of Robust Z-
scores for each gene assayed in duplicate. VSFs (376) and VRFs (161) are noted. D. Bioinformatics show fraction of candidate genes that have human
or mosquito orthologs. Significant enrichment of conserved genes (p,0.0001) and under-enrichment of Drosophila-specific genes (p,0.0001) as
analyzed by chi-squared test. E. Pie chart of candidate genes and validation results (50 VRF, 96 VSF, 71 not validated). F–G. Gene ontology
enrichment of validated genes with five or more members displayed (p,0.001). F. VSF categories enriched. G. VRF categories enriched.
doi:10.1371/journal.ppat.1003914.g001
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include the remaining 17 genes in the complex, the screen
identified 96 VSFs and 50 VRFs in total (Figure 1E; Table S1
and S2).
Bioinformatics analysis was used to identify processes or
pathways that impact WNV infection. First, we performed Gene
Ontology enrichment analysis on the VSF and VRF gene sets
independently (Figure 1F and G) and found biological pathways
including vesicle-mediated transport and membrane modifications
were enriched within the VSF data set, consistent with the
important role of vesicular trafficking and membrane modifica-
tions in WNV entry and replication [6]. Second, we used several
functional annotation metrics to place these validated genes into
cellular pathways and sub-cellular compartments most likely
relevant to WNV infection (red genes, VRF; green genes, VSF;
black genes not tested but in validated complexes; Figure S1G in
Text S1). We identified 29 genes involved in endocytosis and
endosomal acidification, a known entry pathway for WNV.
Furthermore, although we tested and validated only 4 of the
components in the signal recognition particle complex, we
identified 6 subunits of this complex in our primary screen,
supporting the importance of targeting the WNV polyprotein to
the ER for proper translation and processing. These findings
suggest that this screen was robust and identified important host
factors that promote infection.
The VRFs were highly conserved (86% have human orthologs)
and fell into distinct enriched groups. Two of the three categories
involved RNA metabolism, including RNA transcription, which
may be involved in an antiviral transcriptional program [31]. In
fact, 28% of the WNV VRFs (p,0.00012) have a function within
the nucleus suggesting a complex host response to infection since
WNV replicates exclusively in the cytoplasm (Figure S1F in
Text S1).
Identification of broadly antiviral factors in vector-borne
virus infections
While few antiviral pathways have been described in Drosophila,
the well characterized ones (e.g., RNA silencing machinery)
appear to inhibit infection of diverse viruses [38,39]. Given this,
we explored whether the anti-WNV factors identified also
restricted other viral pathogens. We tested two additional
flaviviruses: the WNV strain Kunjin (CH 16532; WNV-KUN)
and Dengue virus (Drosophila adapted Dengue-2 (DENV)). In
addition we tested three additional human vector-borne viruses:
Sindbis virus (HRsp; SINV), Rift Valley Fever virus (MP12;
RVFV), and vesicular stomatitis virus (Indiana; VSV) (Figure 2A).
All of these are enveloped RNA viruses transmitted to vertebrates
by an insect vector. While mosquitoes are the natural vector for
WNV, WNV-KUN, DENV, SINV and RVFV, sandflies are the
primary vector for VSV. The flaviviruses and SINV are positive
sense RNA viruses, whereas RVFV and VSV are negative sense.
RVFV has a tri-segmented genome, while the other viruses encode
a non-segmented genome. Thus, these viruses represent divergent
families and genomic architectures.
We and others have previously infected Drosophila with WNV,
DENV, SINV, RVFV and VSV [24,25,40,41,42]. However,
WNV-KUN infection of Drosophila has not been characterized.
WNV-KUN is a less pathogenic strain of WNV endemic to
Oceania [5]. We found that WNV-KUN, analogous to WNV New
York, productively infected Drosophila cells (Figure S2A and B in
Text S1). Next, we optimized conditions for RNAi screening in
384 well plates using both negative and positive control dsRNAs
based upon our previous studies selecting conditions to identify
restriction factors for WNV-KUN, DENV, SINV, RVFV and
VSV (Figure S2C–G in Text S1) [25,40,41]. We screened the
validated WNV gene set in duplicate against each virus, and Z-
scores were calculated (Table S3). We used hierarchical clustering
to compare the VRF gene dependencies of all six viruses
(Figure 2B). The four positive sense viruses clustered together
(flaviviruses WNV, WNV-KUN, and DENV, and alphavirus
SINV), while RVFV and VSV, the two negative sense viruses
clustered together. This suggests the gene signature of restriction is
related to a fundamental aspect of viral structure.
The WNV VRFs had a high propensity to impact infection by
multiple different viruses. There was a high concordance of gene
dependencies across the three flaviviruses; 31 genes (86%)
restricted WNV-KUN and 22 genes (61%) restricted DENV
(Figure 2C and Table S3). There also was a large overlap
between WNV and SINV VRFs (64%), while less so with RVFV
(38%) and VSV (25%). Thus, many anti-WNV factors appear
broadly antiviral against other flaviviruses and an unrelated
positive strand RNA virus in insect cells. The degree of VRF
overlap diminished as the viruses became more disparate
(Figure 2C). Nonetheless, we identified 7 host factors that
significantly restricted infection by all six vector-borne viruses
tested (p,0.05): dXPO1 (emb), dRUVBL1 (pont), dYARS (Aats-
tyr), dEIF1B (CG17737), dPPM1L (CG7115), dCTNS (CG17119)
and dICT1 (CG6094). All seven of these VRF genes have human
and mosquito orthologs (Figure 2D).
dRUVBL1 and the Tip60 complex restrict vector-borne
virus infection in Drosophila
Among the validated WNV VRFs, genes with putative nuclear
roles were enriched (p,0.00012) and included dRUVBL1 (pontin,
also known as Tip49), which was antiviral against all six viruses.
RUVBL1 is an ATP-binding protein belonging to the AAA+
(ATPase associated with diverse cellular activities) family of
ATPases implicated in diverse cellular pathways in the nucleus
and cytoplasm [43,44,45,46,47,48,49]. First, we validated the
antiviral activity of dRUVBL1 using independent dsRNA
targeting dRUVBL1 outside of the screening format and observed
a significant increase (p,0.05) in infection by WNV, WNV-KUN,
DENV, SINV, RVFV and VSV compared to control (Figure 3A
and B). There was no impact on cell number upon depletion of
dRUVBL1 (Figure S3A in Text S1). Next, using quantitative
RT-PCR (RT-qPCR) as an independent assay, we found that both
WNV and VSV RNA levels were increased upon dRUVBL1-
depletion compared to the control (Figure 3C and D).
One advantage of the Drosophila system is the powerful genetic
tools including the availability of genome-wide in vivo RNAi
transgenic flies. Furthermore, Drosophila are not hematophagous,
so they can be challenged easily and safely with highly pathogenic
human viruses. We took advantage of WNV-KUN as it is a BSL2
agent in comparison to the more virulent North American WNV
strains, which require a BSL3 facility [50]. Wild-type flies were
permissive to WNV-KUN infection as measured by plaque assay
and exhibited no increase in mortality compared to control flies
(Figure S3B and C in Text S1). This is consistent with the
natural infection of mosquitoes where limited pathogenesis is
observed, and similar to our observations with other vector-borne
viruses (VSV, SINV, RVFV) that display limited pathology upon
viral infection [25,40,41]. However, loss of innate immune
defenses in Drosophila or mosquitoes can render insects more
susceptible to infection and result in increased viral replication and
mortality [19,20,21,40,51,52,53]. Because null mutants in
dRUVBL1 are lethal, we took advantage of inducible RNAi
transgenic flies [54]. We used the GAL4/UAS system to promote
expression of a UAS- inverted repeat (IR) transgene that bears
long hairpin dsRNA against dRUVBL1 to target the endogenous
Broadly-Acting Anti-Arboviral Host Factors
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transcript in vivo. We induced expression of the transgene using a
heat shock (hs) promoter in adult flies allowing us to bypass any
developmental requirements. Indeed, expression of the hairpin
during development was lethal (data not shown). Importantly, heat
shock driven dRUVBL1 RNAi flies had decreased dRUVBL1
mRNA (Figure S3D in Text S1). Next, dRUVBL1-depleted (hs-
GAL4,dRUVBL1 IR) and control flies (hs-GAL4,+) were
challenged with WNV-KUN and survival was monitored.
Unchallenged dRUVBL1-depleted flies exhibited no increase in
mortality nor did control flies challenged with WNV-KUN.
Notably, the majority of WNV-KUN infected dRUVBL1-
depleted flies succumbed to infection (p,0.01, Figure 3E). We
next tested if there was an impact on viral load. Groups of 15 flies
were challenged, and whole animals were crushed, and assayed for
WNV-KUN by plaque assay in four independent experiments
(shown as individual dots). We observed modest, but increased
viral loads in dRUVBL1-depleted animals compared to controls
(set to 1) at day 6 post infection; similar results were observed at
day 9 post infection (Figure 3F, not shown).
We subsequently explored the requirement of dRUVBL1
during VSV infection, the best-studied human arbovirus in flies,
and most divergent from WNV of the vector-borne viruses tested
(Figure 2C). Again, while uninfected flies or wild type control flies
challenged with VSV exhibited little mortality, flies depleted for
dRUVBL1 and challenged with VSV showed an increase in
mortality after infection (p,0.01, Figure 3G). Groups of 15 flies
were challenged, and whole animals were crushed, and assayed for
VSV by plaque assay in seven independent experiments (shown as
individual dots). We observed modest, but increased viral loads in
dRUVBL1-depleted animals compared to controls (set to 1) at day
6 post infection (Figure 3H). Together, these results demonstrate
the important and broad-spectrum antiviral requirement for
dRUVBL1 both in vitro and in vivo in Drosophila.
dRUVBL1 has been shown to function in many complexes,
most often in conjunction with another AAA+ ATPase,
dRUVBL2 (reptin, also known as Tip48) (depicted in
Figure 4A) [43,54]. Indeed, structural and functional analysis of
human and yeast RUVBL1 and RUVBL2 suggest these proteins
Figure 2. Comparisons of virus dependencies. A. Table listing the vector-borne viruses tested and general classifications based on virus family,
genome structure, and natural vector. B. A hierarchical heat map of six viruses screened displaying Robust Z-scores for each VRF against WNV, WNV-
KUN, DEN, SINV, RVFV, and VSV. C. Percentage of WNV VRFs that also restricted the indicated virus. D. Table of the seven Drosophila genes that had
antiviral activity against all six viruses tested. Human and mosquito orthologs are listed.
doi:10.1371/journal.ppat.1003914.g002
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work as a scaffold in addition to functioning as ATPases,
potentially explaining their association with a diverse set of
cellular complexes [44]. dRUVBL1, along with dRUVBL2, is
involved in chromatin remodeling, most notably in the Ino80 and
Tip60/Swr1 complexes [55,56]. Furthermore, roles in transcrip-
tional regulation facilitating the activity of c-Myc and b-catenin
also have been reported in Drosophila and human cells [57,58].
Additional roles for dRUVBL1 and dRUVBL2 have been
described in snoRNA maturation, nonsense mediated mRNA
decay, and telomere maintenance. Lastly, dRUVBL1 also has
been implicated in chromatin remodeling with the Drosophila
Trithorax complex, although this is thought to be independent of
dRUVBL2 [46]. Based on these possible functions, we tested
components of these complexes for their impact on viral infection
to identify which of the putative dRUVBL1 containing complex(-
es) mediated the antiviral activity. We designed dsRNAs against
dRUVBL2 along with the indicated genes in each of the
complexes in Figure 4A. Cells were treated with these dsRNAs,
along with b-gal (negative) and dRUVBL1 (positive) controls.
Importantly, no impact on cell viability was observed (Figure S4A
Figure 3. dRUVBL1 is a broadly antiviral gene. A. Representative images of Drosophila cells treated with control (b-gal) or dRUVBL1 dsRNA, and
infected with WNV, WNV-KUN, DEN, SIN, RVFV, or VSV (blue, nuclei; green, virus). B, Quantification of fold change in infection for dsRNA treated cells
as in A. Mean 6 SD for 3 independent experiments; * p,0.05, ** p,0.01. C–D. Viral RNA levels measured using qRT-PCR in Drosophila cells treated
with b-gal (control) or dRUVBL1 dsRNA infected with WNV (C) or VSV (D) Mean6 SD of fold change for 3 independent experiments; ** p,0.01. E–H.
Adult flies of the indicated genotypes were challenged with vehicle or WNV-KUN (E–F) or VSV (G–H). Mortality was monitored as a function of time
post-infection (E,G) (log rank: * p,0.05, ** p,0.01). (F,H) Groups of 15 flies of the indicated genotypes were challenged, and viral titers were
assessed by plaque assay in 4–7 independent experiments (shown as individual dots) with controls (set to 1) and fold change shown at day 6 post
infection. Line represents mean.
doi:10.1371/journal.ppat.1003914.g003
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in Text S1). Next, the dsRNA treated cells were infected with
either WNV or VSV. Depletion of c-Myc, arm (Drosophila b–
catenin), Smg1, Fib and Nop60B did not impact WNV or VSV
infection levels (Figure 4B and C). In contrast, dRUVBL2 was
antiviral against both VSV and WNV (Figure 4B and C).
Depletion of both dRUVBL1 and dRUVBL2 together did not
increase infection beyond that observed with silencing of either
gene, indicating their effect was not additive (data not shown).
Increased WNV and VSV infection also was observed when
dTIP60 (Tip60), dEP400 (domino (dom)) and dSMARCA4
(Brahma (brm)) were depleted. Since dRUVBL1, dRUVBL2,
dEP400 and dTIP60 are all antiviral, and members of the Tip60
complex, these data suggest that a major antiviral role of
dRUVBL1 is through its function in the Tip60 complex.
Next, we tested whether Tip60 also restricted infection of adult
flies. Indeed, we depletion of Tip60 using in vivo RNAi led to
decreased survival of flies challenged with WNV-KUN and VSV
but did not impact survival of unchallenged animals (Figure
S4E–G in Text S1). Thus, the Tip60 complex also has antiviral
roles in vivo.
Tip60 complex is antiviral in mosquito cells
Mosquitoes are the natural vectors for WNV, WNV-KUN,
DENV, RVFV and SINV although the particular mosquito
species that transmit each of these viruses varies [59,60]. In
contrast, the primary vector for VSV is the sandfly, although VSV
has been isolated from mosquitoes [61]. Aedes aegypti is the primary
vector species for DENV transmission, and can be infected by
RVFV, WNV, WNV-KUN, and SINV [62]. Furthermore, the
Aedes aegypti genome has been sequenced [63] and the Aedes aegypti
cell line Aag2 is amenable to RNAi and routinely used as a model
for mosquito cell studies [64].
We designed dsRNAs against Aedes aegypti RUVBL1
(AAEL004686), RUVBL2 (AAEL010341), and TIP60
Figure 4. Tip60 complex has antiviral activity. A. Table of RUVBL1-associated complexes, whether the complex is dependent on RUVBL2, and
other genes in the complexes tested for antiviral activity. Genes in red were found to be antiviral against both WNV and VSV. B–C. DL1 cells were
treated with the indicated dsRNA and then infected with (B) WNV or (C) VSV. Mean 6 SD of fold change in percent infection compared to control
(bgal dsRNA) for 3 independent experiments; * p,0.05, ** p,0.01. D–E. Aag2 cells were treated with the indicated dsRNA and then infected with (D)
WNV-KUN or (E) VSV. Mean 6 SD of fold change in percent infection compared to control (bgal dsRNA) for 3 independent experiments; * p,0.05,
** p,0.01.
doi:10.1371/journal.ppat.1003914.g004
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(AAEL014072) orthologs. Prior to infection, Aag2 cells were
treated with these dsRNAs or with dsRNAs against Bgal or the
viral genome as negative and positive controls, respectively. Loss of
RUVBL1, RUVBL2, or TIP60 mosquito orthologs did not affect
cell number (Figure S4B in Text S1) but led to a significant
increase in WNV-KUN infection (p,0.05, Figure S4C in Text
S1 and Figure 4D). Similarly, each of these genes had antiviral
effects against VSV, as silencing resulted in increased infection
(p,0.05, Figure S4D in Text S1 and Figure 4E). These data
indicate that members of the Tip60 complex also have antiviral
activity in cells from a mosquito vector.
Export receptor, dXPO1, restricts virus infection in
Drosophila
dXPO1 (embargoed (emb), also known as CRM1), another
broadly antiviral gene identified in our screen, is a nuclear export
receptor conserved from yeast to humans. XPO1 shuttles proteins
and RNAs from the nucleus to the cytoplasm [65,66]. To validate
the role of dXPO1 in viral infection we tested whether an
independent dsRNA against dXPO1 modulated infection. Silenc-
ing of XPO1 with an independent dsRNA did not impact cell
number (Figure S5A in Text S1) but resulted in to 2 to 4-fold
increases in the percentage of cells infected with WNV, WNV-
KUN, DENV, SINV, RVFV or VSV as measured by microscopy
(p,0.05, Figure 5A and B). Consistent with this, loss of dXPO1
led to a $6-fold increase in both WNV and VSV RNA, as
measured by RT-qPCR (p,0.05, Figure 5C and D). Thus, a
loss of dXPO1 expression leads to increased viral replication in
Drosophila cells.
Next, we assessed whether dXPO1 was antiviral in vivo in adult
flies. Null mutants of dXPO1 are lethal [67] so we again used an
inducible RNAi and observed in vivo silencing of the mRNA
(Figure S5B in Text S1). We then challenged control (hs-
GAL4.+) or dXPO1-depleted (hs-GAL4.dXPO1 IR) flies with
vehicle, WNV-KUN or VSV. While unchallenged flies or control
challenged flies did not exhibit increased mortality, dXPO1-
depleted flies challenged with either WNV-KUN or VSV had
increased mortality (p,0.01, Figure 5E and F). Furthermore,
dXPO1-depleted flies had modestly increased WNV-KUN viral
loads, as measured by plaque assay of whole flies in four
independent experiments (individual dots) relative to control (set
to 1) (Figure 5G). And increased VSV loads, as measured by
plaque assay of whole flies in three independent experiments
(individual dots) relative to control (set to 1) (Figure 5H). These
results establish that dXPO1 is required for antiviral defense both
in cells and at the organismal level in adult flies.
XPO1 is antiviral in mosquito cells
To assess whether XPO1 also had antiviral activity in the vector
mosquito cells, we treated Aag2 cells with dsRNAs against the
Aedes aegypti XPO1 ortholog (AAEL001484) or against Bgal or the
viral genome as negative and positive controls, respectively. These
cells were subsequently challenged with WNV-KUN or VSV.
While depletion of XPO1 did not affect cell number (Figure S5B
in Text S1), we observed a significant increase in the percentage
of Aag2 cells infected with WNV-KUN or VSV (p,0.05, Figure
S5C and D in Text S1 and Figure 5I and J).
Aldolase, a target of dXPO1 nuclear export, is antiviral
Since dXPO1 is as a nuclear export receptor, we speculated that
dXPO1-dependent regulation of either host genes required for
infection or virus-induced antiviral genes may account for the
antiviral activity. Indeed, antiviral transcriptional programs have
been shown to restrict viral infections in Drosophila
[19,31,52,68,69]. Leptomycin B (LMB) is a potent and specific
inhibitor of dXPO1 mediated nuclear export [70]. Previous work
demonstrated that LMB treatment of Drosophila cells altered the
nuclear export of only 85 mRNAs (,2% of the transcripts
surveyed) [71]. One gene, bsg, was XPO1-dependent and
required for WNV infection. However, this cannot explain the
phenotype of XPO1 because bsg was required for WNV infection
and not the other viruses that are sensitive to XPO1 restriction
(Table S3). Moreover, 2 XPO1-dependent genes also were
transcriptionally induced by VSV infection (CG4294, CG30389)
[31]. We generated dsRNAs targeting CG4294 and CG30389 but
observed no impact on WNV-KUN or VSV infection (Figure 6C
and D). None of the 50 VRFs from our screen were within this
set; however, data mining of an RNAi screen with VSV in DL1
cells (S. Cherry unpublished data) identified one additional gene
(Aldolase, dALDOA) from this LMB-dependent gene set that
showed antiviral activity against VSV (Figure 6A). We generated
an independent dsRNA targeting dALDOA and observed that
depletion did not affect cell number (Figure S6A in Text S1) but
resulted in a 1.5 to 2.5-fold increase (p,0.05) in the percentage of
cells infected with WNV-KUN and VSV, respectively (Figure 6C
and D). This suggests that dXPO1-dependent mRNA export of
dALDOA contributes to the defense against multiple virus
families.
Aldolase is a critical enzyme in glycolysis, catalyzing the
conversion of fructose 1,6-biphosphate to glyceraldehyde-3-phos-
phate (G3P) and dihydroxyacetone phosphate (DHAP)
(Figure 6B). However, Aldolase may have functions apart from
glycolysis, as its expression but not all core glycolytic enzymes are
increased in response to LPS treatment [72]. To define whether
the antiviral activity of Aldolase was related to glycolysis we
performed two complementary experiments. First, we depleted
Drosophila cells of additional enzymes essential for glycolysis
(Phosphoglucose isomerase (Pgi), Phosphofructokinase (Pfk), Phos-
phoglycerate kinase (Pgk), and Phosphoglycerate mutase
(Pglym87)) (Figure 6B). Depletion of these canonical glycolysis
enzymes had no impact on cell number (Figure S6A in Text S1)
or WNV-KUN and VSV infection (Figure 6C and D). Second,
to overcome the fact that RNAi is incomplete, and that these are
enzymes which may be fully active at low levels, we took
advantage of two specific and potent glycolysis pathway inhibitors,
Dichloracetic Acid (DCA), which inhibits the enzyme pyruvate
dehydrogenase kinase, and a hexokinase inhibitor (3Br) [73].
Neither of these treatments impacted cell number (Figure S6B–E
in Text S1) or WNV-KUN and VSV infection of Drosophila cells
(Figure 6B–D). Together, these data suggest the antiviral effect of
Aldolase is not mediated through the glycolysis pathway.
XPO1 and RUVBL1 have antiviral activity in mammalian
cells
As dRUBVL1 and dXPO1 are conserved from insects to
mammals, we tested whether silencing of these genes in human
cells impacted infection. For these studies, we transfected human
osteosarcoma U2OS cells with siRNAs against a non-targeting
control, hRUVBL1 or hXPO1. Three days later, we confirmed
silencing of these genes by RT-qPCR (Figure S7A and B in
Text S1) with no impact on cell number (Figure S7C in Text
S1). Next, the cells were infected with WNV-KUN (MOI of 0.5),
and infection levels were monitored using immunofluorescence
20 hpi. Loss of either hRUVBL1 or hXPO1 resulted in a 2 to 3-
fold increase in the percentage of WNV-KUN-infected cells, as
measured by microscopy (p,0.05, Figure 7A). Consistent with
this, we observed an increase in viral RNA levels in cells depleted
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of hRUVBL1 or hXPO1 as measured by Northern blot and
quantified (p,0.05, Figure 7B). Similarly, depletion of
hRUVBL1 or hXPO1 enhanced VSV infection, as measured by
the percentage of infected cells (p,0.05, Figure 7C) or levels of
viral RNA (p,0.05, Figure 7D). Furthermore, we tested whether
RUVBL1 likely acted through the same Tip60 complex as we
found in Drosophila. To this end, we obtained independent siRNAs
against hTIP60 (KAT5) and confirmed they reduced TIP60
expression in human 293T cells as measured by RT-qPCR
(Figure S7D in Text S1). Furthermore, we observed significantly
increased WNV infection in the depleted cells (Figure 7E).
Together, these data suggest that the Tip60 complex is antiviral
against multiple viruses and in disparate hosts ranging from insects
to vertebrates.
Our initial studies in Drosophila were performed in a single round
of infection suggesting that the requirements for the genes in the
viral lifecycle included: entry, uncoating, translation, polyprotein
processing, and RNA replication. To study the step in the viral
lifecycle impacted by the Tip60 complex in mammalian cells we
took advantage of a human cell line (293T) that stably maintains a
subgenomic WNV replicon expressing GFP [74,75]. If these genes
restricted infection downstream of entry, but upstream of
assembly, they should restrict the replication of this WNV
replicon. Indeed, siRNA depletion of hRUVBL1 or hTIP60 led
to increased levels of WNV replicon replication as measured by
immunoblot (Figure S7E in Text S1). Therefore, the action of
these genes is at the step of translation, polyprotein processing, or
RNA replication.
Since WNV is a neurotropic virus we tested whether RUVBL1
restricted infection in primary neuronal cultures. We prepared
cerebellar granule cell neurons from wild-type C57BL/6 mice and
transduced them with lentiviruses expressing either a control
shRNA, or 4 independent shRNAs against RUVBL1. Three days
later, we challenged the cells with WNV (MOI= 0.1), and
harvested virus in the supernatant 24 hours later. Notably, all
four independent shRNA depleted RUVBL1 to varying extents
(Figure S7F in Text S1), and the level of depletion correlated
with a significant increase in viral titers (p,0.05, Figure 7F).
Figure 5. dXPO1 has antiviral activity in insects. A. Representative images of Drosophila cells treated with control (b-gal) or dXPO1 dsRNA, and
infected with WNV, WNV-KUN, DEN, SIN, RVFV, or VSV (blue, nuclei; green, virus). B. Quantification of fold change in infection for dsRNA treated cells
as in A. Mean 6 SD for 3 independent experiments; * p,0.05, ** p,0.01. C–D. Viral RNA levels measured using RT-qPCR in Drosophila cells treated
with b-gal (control) or dXPO1 dsRNA and infected with WNV (C) or VSV (D). Mean 6 SD of fold change for 3 independent experiments; * p,0.05. E–
H. Adult flies of the indicated genotypes were challenged with vehicle or WNV-KUN (E, G) or VSV (F, H) and mortality (E, F) was monitored as a
function of time post-infection (** p,0.01 log rank). (G, H) Groups of 15 flies of the indicated genotypes were challenged, and viral titer was assessed
by plaque assay in 3 or 4 independent experiments (shown as individual dots) with controls (set to 1) and fold change shown at day 6 post infection.
Line represents mean. I–J. Aag2 cells were treated with the indicated dsRNA and then infected with (I) WNV-KUN or (J) VSV. Mean 6 SD of fold
change in percent infection compared to control (b-gal dsRNA) for 3 independent experiments; * p,0.05, ** p,0.01.
doi:10.1371/journal.ppat.1003914.g005
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These data demonstrate that RUVBL1 restricts WNV infection in
primary neurons.
To confirm a role for hXPO1 in antiviral defense in human cells
using a small molecule inhibitor to complement our RNAi studies,
we treated U2OS cells with the XPO1 export inhibitor LMB and
monitored WNV-KUN or VSV infection. Treatment with LMB
significantly enhanced (2–3 fold) viral replication by both viruses
(p,0.05, Figure 7G and H), as measured by an increase in the
percentage of infected cells. LMB treatment did not impact cell
number (Figure S7G in Text S1). Furthermore, siRNA-
mediated depletion of hXPO1 or LMB treatment of 293T cells
carrying a WNV replicon revealed that the dependence was again
downstream of entry and upstream of assembly since both
perturbations led to increased levels of replication (Figure S7E
and S7H in Text S1). These data suggest that the hXPO1 has
antiviral activity through the regulation of XPO1-dependent cargo
export downstream of entry in evolutionarily diverse cell types
from insects to mammals.
Discussion
Genome-wide RNAi screens have been employed to identify
cellular factors required by viruses to successfully infect cells as well
as factors that, if left unmodulated by the virus, serve to suppress
infection. In addition, this screening approach can identify
pathways that regulate the expression and activity of direct
antiviral factors, orchestrating a robust antiviral response. Since
our goal was to identify conserved inhibitory pathways that span
insects and mammals with a particular interest in those having
broad antiviral activity against disparate viruses, we performed a
Figure 6. dXPO1 targets dALDOA and restricts viral infection. A. Table of genes whose mRNA export is LMB-dependent, their level of
induction by VSV infection, and whether they have been identified as antiviral previously. B. Schematic overview of glycolysis pathway (red, Aldolase
(Ald); blue, enzymes tested; black, enzymes not tested; green, inhibitors). C–D. DL1 cells were treated with the indicated dsRNA and then infected
with (C) WNV-KUN or (D) VSV. Data is presented as Mean 6 SD of fold change in percent infection compared to control (b-gal dsRNA) for 3
independent experiments; * p,0.05.
doi:10.1371/journal.ppat.1003914.g006
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genome-wide RNAi screen in Drosophila in which we deliberately
set a low infection rate, thereby sensitizing our assay to detect
factors that when suppressed result in higher levels of infection.
This is in contrast to previous genome-wide flavivirus RNAi
screens, which targeted a higher level of infection and so led to the
identification of a larger number of genes that promote infection
[24,32]. Nonetheless, our screen was sufficiently sensitive and
robust to enable us to identify 96 genes that promoted WNV
infection. Enriched gene ontology categories included pathways
such as clathrin-mediated endocytosis and endosomal acidification
that are required for flavivirus entry and were identified by earlier
RNAi screens.
We identified 50 restriction factors, greatly expanding the
number of cell intrinsic anti-WNV factors known
[32,76,77,78,79,80]. We compared our restriction factors with
previous studies (Table S4). A genome-wide siRNA screen against
WNV in human cells identified 22 genes that were antiviral of
which 6 had Drosophila homologs; none of which were within our
validated antiviral genes [32]. A genome wide screen against
hepatitis C virus, a distantly related Flaviviridae family member, in
human cells identified 25 antiviral genes of which 12 had
Drosophila orthologs; again, none of which were within our gene
set [81]. Two screens querying the antiviral role of interferon
stimulated genes (ISGs) against flaviviruses were recently published
[80,82]; however, none of our antiviral genes are known ISGs.
The Schoggins screen identified 47 ISGs that when ectopically
expressed restricted a flavivirus amongst which there were 12
homologs in Drosophila; none of which we identified as antiviral
in our screen. The Li screen identified 47 ISGs that when depleted
by RNAi restricted infection amongst which 13 had homologs in
Drosophila; none of which were identified in our screen. None of
the Drosophila homologs from any of these screens were within any
Figure 7. RUVBL1 and XPO1 restrict viral infection in mammalian cells. A–D. Human U2OS cells were transfected with siRNAs against a
control, hRuvBL1, or hXPO1 and challenged 3 days post transfection with WNV-KUN for 20 hours (A–B) or VSV for 12 hours (C–D). Cells were fixed,
processed for microscopy and quantified in A, C. Mean 6 SD of fold change compared to control for 3 independent experiments; * p,0.05,
**p,0.01. Cells were processed for northern blots and quantified displaying the mean for 3 independent experiments with control set to 1; * p,0.05,
**p,0.01 in B, D. E. 293T cells were transfected with siRNAs against control or two independent siRNAs against hTIP60 and challenged 3 days post
transfection with WNV for 24 hours and processed by flow cytometry. Three independent experiments were quantified; Mean 6 SD of the fold
change in infection is shown and normalized to the control; **p,0.01. F. Primary neurons transduced with lentiviruses expressing the indicated
shRNAs were infected with WNV for 24 hours and processed for viral yield by focus forming assays. Mean 6 SD for 3 independent experiments;
* p,0.05, **p,0.01. G–H. U2OS cells were treated with vehicle or LMB and infected with (G) WNV-KUN or (H) VSV. Mean 6 SD of fold change in
percent infection compared to control (vehicle) for 3 independent experiments; * p,0.05, ** p,0.01.
doi:10.1371/journal.ppat.1003914.g007
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other screen making conclusions difficult. Additional screens
performed at low levels of infection may reveal additional intrinsic
restriction factors.
Unexpectedly, our antiviral gene set was enriched for nuclear
functions such as RNA metabolism and transcription even though
WNV replicates exclusively in the cytoplasm. This observation
suggested that we had uncovered pathways and processes that
orchestrate an antiviral response rather than factors that interact
directly with the virus. If this were the case, as is seen with antiviral
interferon (IFN) responses in mammals, we reasoned that many of
the VRFs might have antiviral activities against additional viruses.
This in fact proved to be the case - not only did we discover a high
degree of concordance between the WNV, WNV-KUN and DEN
VRFs (WNV-KUN 86%, 31 genes; DENV 61%, 22 genes), we
identified seven genes that restricted infection of all six different
arboviruses tested, which included both positive and negative-sense
RNA genomes: dYARS (Aats-tyr), dEIF1(CG17737), dPPM1L
(CG7115), dCTNS (CG17119), dICT1 (CG6094), dXPO1 (emb),
and dRUVBL1 (pont). Since none of these genes have been
suggested previously to have an antiviral role in insects, we chose
two genes for more detailed analysis: dRUVBL1 and dXPO1.
RUVBL1 had antiviral activity in Drosophila and mosquito cells.
Depletion of dRUVBL1 in adult flies converted a non-pathogenic
infection by WNV-KUN or VSV into a pathogenic infection with
increased mortality and viral replication. These data suggest that
RUVBL1 has a highly conserved role in antiviral defense in insects,
including mosquito vectors. RUVBL1 is an AAA+ ATPase
implicated in many cellular pathways [43] and that interacts with
a number of other molecules that impact its function. By
methodically suppressing each of its known interacting partners,
we found that components of the Tip60 chromatin-remodeling
complex (TIP60, EP400 and RUVBL2) that regulates transcription
[43] were antiviral against multiple viruses in Drosophila and
mosquito cells. dTip60 also was antiviral in adult flies. Furthermore,
silencing of RUVBL1 led to increased viral infection in human
cultured cells and primary mouse neurons. Silencing of TIP60 in
human cells also rendered them more susceptible to WNV infection.
Together, these results suggest a conserved role for the Tip60
complex in antiviral defense across phylogeny. WNV subgenomic
replicons were used to show that the requirement for these genes in
restriction is downstream of entry and upstream of viral assembly,
suggesting a restriction of translation, polyprotein processing and/or
RNA replication. While further investigation is required to
determine the Tip60 targets that are responsible for the antiviral
activity and the precise step of the lifecycle impacted, the
identification of a chromatin remodeling complex as broadly
antiviral is intriguing. Innate immunity is controlled, in large part,
through the tight regulation of sequential gene expression programs
that have effector function to restrict pathogen replication. We
recently characterized a complex and rapid transcriptional antiviral
host program active in insects that includes both primary responses
which are translation-independent and secondary responses that are
translation-dependent [31]. Half of this response was controlled at
the level of transcriptional pausing, which also plays a role in innate
immune responses in mammals [31,83,84,85]. This antiviral
transcriptional program was active against a broad panel of viruses,
as we found with the Tip60 complex here. Thus, we hypothesize that
the Tip60 chromatin remodeling complex may contribute to the
orchestration of this sophisticated antiviral transcriptional response.
A recent study found that RUVBL2 was antiviral against
influenza virus by interfering with nucleoprotein (NP) oligomer-
ization that drives viral RNA polymerase activity in the nucleus;
however, in contrast to our findings, this effect was independent of
RUVBL1 function [86]. This may be a distinct and direct role for
RUVBL2 in influenza replication independent of the role for the
Tip60 complex in antiviral defense.
Many viruses, including those used in our studies inhibit host
transcriptional responses to prevent the induction of antiviral
mRNAs including IFN genes. Whether viruses target this Tip60
complex to block an antiviral transcriptional program is unknown.
Tip60 is degraded by a number of nuclear viruses including HIV,
adenovirus, papilloma virus and cytomegalovirus to promote viral
replication [87,88,89,90]. This is thought to alleviate its repression
of early gene transcription. Whether these virus interactions alter
the activity of the Tip60 complex on antiviral gene expression
remains unknown.
The second broadly-acting VRF we investigated was XPO1. At
the organismal level depletion of dXPO1 enhanced viral replication
and mortality by both WNV-KUN and VSV. Data from yeast and
humans suggest that XPO1 is a nuclear export receptor responsible
for the translocation of RNAs and proteins from the nucleus to the
cytoplasm [91,92]. However, more recent studies have suggested
that the mRNA cargo dependent on XPO1 is limited [71,93].
Inhibition of XPO1 either by RNAi or using the specific inhibitor
LMB, which blocks the nuclear export function of XPO1, resulted
in increased viral infection, which suggests the antiviral role of
XPO1 is at the step of nuclear export. As the vector-borne RNA
viruses studied here replicate exclusively in the cytoplasm, we
hypothesize that XPO1 transports cellular mRNAs critical for an
antiviral response. Indeed, viruses including VSV (used in our
study), HIV, VEEV, ebolavirus and picornaviruses inhibit nuclear
export of antiviral genes including ISGmRNAs required for defense
in mammalian cells [94,95,96,97,98,99,100,101]. Consistent with
this, LMB inhibition of XPO1 mediated export in human cells
suppressed the export of IFNa1 mRNA [99].
While a role for nuclear export in antiviral immunity has been
described in mammalian cells, its function in insect immunity was
unknown. To identify the particular mRNAs responsible for the
antiviral effects of XPO1 in Drosophila we mined a microarray
study of Drosophila cells that found less than 2% of the mRNAs
tested (85 mRNAs) exhibited nuclear export dysregulation upon
LMB treatment [71]. Depletion of one XPO1-dependent mRNA,
dALDOA (Aldolase A), resulted in enhanced virus infection in
Drosophila cells. This suggests that the transport of dALDOA
mRNA plays a role in the innate immune response to vector-borne
viral infections. As part of the glycolysis pathway, ALDOA
enzymatically cleaves fructose 1,6-bisphosphate (F-1,6-BP) into
glyceraldehyde 3-phosphate (G3P) and dihydroxyacetone phos-
phate (DHAP). Our RNAi and pharmacological experiments
suggested the mechanism of viral suppression by ALDOA was
independent of its effects on glycolysis. Future studies will be
required to define mechanistically how ALDOA acts to inhibit
viral infections in insect cells.
Collectively, we have begun to describe a series of conserved
pathways, including transcriptional pausing, chromatin remodeling
and RNA export that likely regulate the expression of gene sets
whose products are antiviral, perhaps in a direct way. For the most
part, virus-host interaction studies have often concentrated on
proteins that interact directly with the virus. Our work has revealed
pathways that orchestrate larger responses, and this confers potent
antiviral activity against a broad range of divergent viruses. Clearly,
there is still much to be learned about the cellular factors critical for
an innate immune response to vector-borne viruses in both
vertebrate and invertebrate hosts. Our identification of these cell-
intrinsic antiviral genes restricting WNV, and in many cases
additional viruses, provides new opportunities for understanding the
control mechanisms and larger antiviral programs active against
globally relevant classes of emerging viral pathogens.
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Materials and Methods
Ethics statement
This animal studies were carried out in strict accordance with
the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee at the Washington University School of Medicine
(Assurance Number: A3381-01).
Cells, antibodies, and reagents
DL1 and Aag-2 cells were grown as previously described [31].
BHK, U2OS, and 293T cells were maintained as previously
described [102]. 293T cells harboring WNV subgenomic replicon
were maintained as previously described [74,75]. Cerebellar
granule cell neurons from neonatal (E6) wild-type C57BL/6 mice
were generated from cerebella dissected in HBSS and dissociated
in 1 mg/ml trypsin with 125 U/ml DNAse (Sigma, St. Louis,
MO) for 20 min. Enzymatic digestion was quenched with
DMEM/10% FCS and the tissue was pelleted, washed in HBSS,
dissociated by trituration through a P-200 pipette tip and layered
on a Percoll gradient. Cells were plated in neurobasal media
(Gibco) supplemented with B-27 serum-free supplement (Gibco)
on poly-D-lysine (PDL)-treated dishes for 1 hour to remove
adherent glial cells. Nonadherent cells were then washed in
HBSS, counted plated on PDL-coated wells in serum-free DMEM
(supplemented with N2 growth medium (Gibco, Grand Island,
NY) and 20 mM KCl. Cultures were .95% pure and were used 3
to 4 days later for lentivirus infections [103]. Antibodies were
obtained from the following sources, anti-WNV NS1 (9-NS1;
[37]), anti-RVFV N (1D8 – gift from C. Schmaljohn), anti-hTIP60
(abcam, ab23886) and Alexa-488 donkey anti-mouse secondary
(Jackson Immunochemicals). The following inhibitors were used:
Leptomycin B (SIGMA) 50 ng/ml; Dichloracetic Acid (SIGMA)
60 mM; Hexokinase II inhibitor II (Calbiochem) 0.1 mM.
Virus stocks
West Nile virus (WNV lineage I strain 3000.0259 New York
2000) was generated in BHK cells, concentrated using Centricon
Plus-70 (Millipore), and ultracentrifuged through a sucrose
cushion as described previously [104]. The WNV-KUNV isolate
(CH16532) was a generous gift of R. Tesh (World Reference
Center of Emerging Viruses and Arboviruses, Galveston, TX) was
propagated using the same protocol as WNV. DENV (gift from M.
Garcia-Blanco) was grown as previously described [24]. SINV was
propagated as previously described [25]. RVFV strain MP12 was
propagated as described [41]. VSV was grown as described [40].
All MOIs were determined on BHK cells.
Drosophila RNAi screen
For the primary WNV screen dsRNAs targeting 13,071 genes
were pre-arrayed in thirty-two 384-well plates at 250 ng per well
(Ambion). 16,000 DL1 cells were seeded in serum-free Schneider’s
media (10 uL/well). One hour later complete media was added
(20 uL/well). Three days post plating, cells were infected with
WNV at an MOI of 10 (10 uL/well). 48 hours post infection cells
were fixed (4% formaldehyde), and a mAb against WNV NS1 (9-
NS1) was used to identify infected cells (anti-mouse Alexa-fluor488
(Jackson Immunochemicals)) and counterstained with Hoechst
33342 to monitor nuclei. 3 images per well were captured at 206
using an automated microscope (ImageXpressMicro) and analyzed
using MetaXpress software. Average infection and nuclei number
were calculated for each site and averaged for each well. The
percent infection was log-transformed, and the median and
interquartile range were used to calculate a z-score: (log10(%infec-
tion)-log10(median))/(IQR*0.74) for each plate. The entire screen
was performed in duplicate and those wells with Robust Z-
scores$to 2.0 or#to22.0 in both replicates were considered ‘hits’.
Similar to the primary screen, secondary screen plates were
arrayed with dsRNA (250 ng) targeting a different region of the
genes identified in the primary screen (DRSC). WNV infections
were performed in duplicate at a higher (20) and lower (5) MOI
(18% and 4% respectively). Infections with other viruses used the
same protocol as WNV and were fixed at the following hours post-
infection: WNV-KUN - 48 hrs (MOI=10), DENV - 72 hrs
(MOI= 10), SINV – 40 hrs (MOI= 5), VSV – 24 hrs (MOI= 1),
RVFV MP12 – 30 hrs (MOI= 1). Robust Z-scores in each
duplicate viral infection set of $1.5 or #1.5 in duplicate (,40%
change) were considered ‘hits’ (p,0.009); none of the negative
controls (non-targeting) were identified as positive, and all of the
positive controls (dsRNA against virus genome) were identified.
Bioinfomatic analysis
The functional annotation and clustering of WNV ‘hits’ was
performed using the DAVID Bioinfomatics resource. Homologene
(NCBI) was used to identify orthologs. Gene Cluster and
TreeView were used to generate heat maps.
Adult infections
All flies were maintained on standard medium at room
temperature. Flies carrying UAS-dXPO1 IR (VDRC v3347) or
UAS-dRUVBL1 IR (VDRC v105408) were crossed to heat shock
(HS)-GAL4 flies (Bloomington) at room temperature. On the day
of injection, the progeny were heat-shocked at 37uC for 1 hour
and shocked every 2 days throughout the experiment. Adults of
the stated genotypes were challenged with WNV-KUN or VSV as
previously described [22]. Groups of at least 20 flies were
challenged for mortality studies. For viral titers, groups of 15 flies
per experimental treatment were crushed and processed at 6 days
post-infection for plaque assays on BHK cells [31].
Quantitative PCR
Total RNA was isolated from infected cells using Trizol
(Invitrogen). For northern blots, RNA species were analyzed as
previously described [105]. For RT-qPCR, cDNA was generated
using random hexamers to prime reverse transcription reactions
using MMLV reverse transcriptase. cDNA samples were treated
with 100 UDNase I (Qiagen) according to manufacturer’s protocol.
Quantitative PCR (qPCR) was performed with the cDNA using
Power SYBR Green PCR Master Mix (Applied Biosystems) and
primers targeting VSV and WNV (VSV For-CGGAGGATT-
GACGACTAATGC, Rev-ACCATCCGAGCCATTCGA: WNV
For-ACATCAAACGTGGTTGTTCCGCTG, Rev-TTGAGGC-
TAGAGCCAAGCATAGCA) in accordance with manufacturer’s
protocol. qPCR conditions were as follows; initial 94uC for 5 min,
then 30 cycles of 94uC for 30 sec, 55uC for 30 sec, and 72uC for
30 sec. Relative viral copy numbers were generated by normalizing
to cells treated with control dsRNA.
Mammalian RNAi
For siRNA treatments, mammalian cells were reverse transfected
with 20 nM siRNA (Ambion: Negative Control#1 (AM4611), GFP
(AM4626), XPO1 (s14937), RUVBL1 (s16370)), KAT5 (s20630,
s20631) using HiPerfect according to the manufacturers protocol
(Qiagen). 60 hours post-transfection, for immunofluorescence, cells
were replated in a 96-well format and infected with either VSV or
WNV-KUN virus 12 hours later. For FACS the cells were infected
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with WNV for 24 hours and stained for NS1 or TIP60 [82] or
infected and processed for northern blot or immunoblot at 12 hr p.i.
for VSV and 20 hr p.i. for WNV-KUN.
For shRNA treatments, lentiviruses (pLK0.1) encoding shRNA
targeting RUVBL1 (clone 1: GCTGGAGATGTGATTTACATT;
clone 2: GCTGGCAAAGATCAATGGCAA; clone 3: GCCACA-
GAGTTTGACCTTGAA; clone 4: GCAAGATATTCTGTC-
TATGAT) or a control (luciferase) were obtained from RNAi Core
facility at Washington University School of Medicine. Lentivirus
particles were generated after co-transfection of HEK-293T cells
with packaging plasmids. Supernatants were collected at 48 hours
later and added to neuron cultures. Three days after transduction,
neurons were infected with WNV (New York 1999 strain) at an
MOI of 0.1. One day later, supernatants were harvested and titered
for virus infection by focus-forming assay [106].
Drug treatments
One day prior to infection U2OS or DL1 cells were seeded in 96-
well plates at 20,000 or 70,000 cells per well respectively.
Leptomycin B (SIGMA) was added at 50 ng/ml to mammalian
cells cells 2 hr prior to infection with WNV-KUN or VSV.
Dichloroacetic Acid (SIGMA) or Hexokinase II inhibitor II
(Calbiochem) were added to U2OS or DL1 cells respectively,
30 minutes prior to infection. Cells were fixed 20 (WNV-KUN) or
12 (VSV) hr post infection, stained and imaged as previously
described.
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